CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...

Cardiovascular disease continues to be the leading cause of death worldwide. But advances in heart-failure therapeutics have ...

Young people’s risk of developing myocarditis is higher and longer lasting after covid-19 infection than after vaccination against it, the largest study of its kind suggests.1 The research—based on ...

The health impact of a Covid infection was higher than the risks from the vaccine for teens and children - but it won't ...